Printer Friendly

AVOS Introduces Medicare Drug Benefit Outlooks Reports; Reports Analyze How Medicare Part D Will Affect the Pharmaceutical Industry.

RALEIGH, N.C. -- The contact information in release should read:
AVOS Life Sciences
John Niedermayer, 919-848-2709
JNiedermayer@AvosLifeSciences.com
or
Maverick Marketing
Megan Haney, 919-459-2768
mhaney@maverickmarketing.com

sted:

AVOS Life Sciences
John Niedermayer, 919-459-2768
JNiedermayer@AvosLifeSciences.com
or
Maverick Marketing
Megan Haney, 919-848-2709
mhaney@maverickmarketing.com



The corrected release reads:

AVOS INTRODUCES MEDICARE DRUG BENEFIT OUTLOOKS REPORTS; REPORTS ANALYZE HOW MEDICARE PART D WILL AFFECT THE PHARMACEUTICAL INDUSTRY

AVOS Life Sciences today announced the availability of Medicare Drug Benefit Outlooks (MDBO), a series of reports that analyze the impact of the Medicare Part D drug benefit on the pharmaceutical industry.

Part D was established by the Medicare Prescription Drug, Improvement and Modernization Act of 2003 and goes into effect January 1, 2006. Although this date is fast approaching, significant questions remain regarding the implications of the Part D drug benefit. MDBO examines the scenarios which may play out over the next three years at the product, drug portfolio and company level, taking into account variables such as Part D enrollment and cost containment strategies.

"This series was born from the need to understand the overall impact of this legislation by the investor community, as well as the pharmaceutical companies themselves," said Neil MacAllister, president of AVOS Life Sciences. "Due to the ambiguity surrounding actual implementation, entities have shied away from quantifying the potential impact of Part D. Our Medicare Drug Benefit Outlooks directly addresses this lack of analysis."

Unlike other analyses that stress the cost of the drug benefit to the taxpayer, MDBO projects revenue forecasts for individual products during the critical time period from 2006 to 2008. This approach allows AVOS to quantify the impact of the drug benefit on each major pharmaceutical company. The framework behind the reports includes the provisions set forth in the legislation, as well as therapeutic and public policy dimensions. As guidelines change and the legislation is implemented, AVOS will update the series to continue to provide competitive intelligence to the pharmaceutical and investment communities.

"Based upon our analysis, there are some clear winners - and some clear losers - in the Part D environment," continued MacAllister. "In the long term, this legislation has great potential to significantly alter the competitive landscape of the pharmaceutical industry."

About AVOS Life Sciences, LLC

AVOS is a boutique advisory and research products firm located in Raleigh, NC, and New York, NY. We specialize in developing and maintaining a leading-edge understanding of the evolving healthcare environment to help our clients position themselves to win in the future. Our unique capabilities are exemplified through AVOS Signals, a research product suite created to provide insight and guidance in product revenue forecasting, future stock performance and exposure to major industry trends. AVOS also offers consulting services where our experts work closely with client teams to respond to specific business needs. For additional information, please visit www.avoslifesciences.com.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Aug 2, 2005
Words:476
Previous Article:Uninterrupted Gameplay Now A Reality with Intec's Unlimited Rechargeable 2.4GHz Wireless Controllers for Xbox(R), PlayStation(R) 2 and GameCube(R);...
Next Article:Arotech Awarded USMC Marine Forces Reserve Driving Simulator Contract.


Related Articles
[R.sub.X] for Seniors.
Pros and Cons of prescription drug benefit changes. (Prescription Drugs).
Drug benefit doubts.
What's the benefit? A new federal Medicare drug plan stimulates independent actions and new ideas, but what's the future role for states?
Medicare Part D: what employers need to know about this voluntary program.
State's Rx for Medicare gaps: some states have made long-term commitments to help their low-income citizens pay their out-of-pocket costs for...
What to do about Medicare Part D; Excerpt from "the Medicare drug benefit: impact on nursing facilities," California HealthCare Foundation.
Extend the deadline.
Drug plan working.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters